Purdue Institute for Drug Discovery

Ampyra

Overview: 

FDA approved for treatment of Multiple Sclerosis 

Ampyra Information

Status: 

Purdue Faculty: 

Dr. Richard Borgens

Dr. Riyi Shi

Dr. Andrew Blight formerly of Purdue now with Acorda Therapeutics

Clinical Trial Information: 

All Amypra Clinical Trials

Development Partner: 

Acorda Therapeutics

Research Articles: 

  Multiple Sclerosis: 

    Treatment of walking impairment in multiple sclerosis with dalfampridine

    A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

  Spinal Cord Injury: 

    The Effects of 4-Aminopyridine on Neurological Deficits in Chronic Cases of Traumatic Spinal Cord Injury in Dogs: A Phase I Clinical Trial

    Pathological changes of isolated spinal cord axons in response to mechanical stretch

    Development of novel 4-aminopyridine derivatives as potential treatments for neurological injury and disease

    4-Aminopyridine derivatives enhance impulse conduction in guinea-pig spinal cord following traumatic injury

  Stroke: 

   Dalfampridine Improves Sensorimotor Function in Rats With Chronic Deficits After Middle Cerebral Artery Occlusion